Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses a pilot study of selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Eric J. Sherman, MD
Advertisement
Articles by Eric J. Sherman, MD
Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of anaplastic thyroid cancer with intensity-modulated radiation therapy (IMRT), paclitaxel, and pazopanib.
Dr. Eric Sherman, Memorial Sloan-Kettering Cancer Center, on the optimal sequencing of cabozantinib and vandetanib for patients with medullary thyroid cancer.
Dr. Eric Sherman, from Memorial Sloan-Kettering Cancer Center, Discusses Vandetanib's Dosage and Precautions
Dr. Eric Sherman from Memorial Sloan-Kettering Cancer Center Discusses the Vandetanib Trial
Advertisement
Latest Updated Articles
Dr. Sherman Discusses the Vandetanib TrialPublished: December 5th 2011 | Updated:
Dr. Sherman on Vandetanib's Dosage and PrecautionsPublished: April 24th 2012 | Updated:
Dr. Sherman on Sequencing Cabozantinib and VandetanibPublished: September 28th 2012 | Updated:
Dr. Sherman on Pazopanib in Anaplastic Thyroid CancerPublished: May 14th 2013 | Updated:
Dr. Sherman on Selumetinib-Enhanced Radioiodine UptakePublished: May 29th 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5